Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R)-Bicalutamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 9/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | GHSR | Q92847 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Bicalutamide SCHEMBL5365801 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL1561110 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL29353850 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL3611 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL1933417 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (R)-Bicalutamide SCHEMBL29354880 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (S)-Bicalutamide SCHEMBL29444530 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (R)-Bicalutamide SCHEMBL28262190 | 0.98 | AR (0.96) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL679554 | 0.97 | AR (0.94) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL15325704 | 0.93 | AR (0.87) | ARCYP2C19ABCB11ALBPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 91377 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4467200-B1 | EZH2 INHIBITION THERAPIES FOR THE TREATMENT OF ANDROGEN RECEPTOR MUTATED PROSTATE CANCERS | CONSTELLATION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260137678-A1 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026102563-A1 | DISUBSTITUTED PYRIMIDOPYRROLE ANALOG AND USE THEREOF | 深圳湾实验室坪山生物医药研发转化中心 | 2026-05-21 | — | — | WO | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-4744666-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | TransThera Sciences (Nanjing), Inc. (CN) | 2026-05-20 | — | — | EP | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| WO-1997005887-A1 | NOVEL COSMETIC AND PHARMACEUTICAL FORMULATION OF ANTIANDROGENS OF NATURAL (PLANT) ORIGIN FOR PERCUTANEOUS TOPICAL APPLICATION | CABO SOLER JOSE (ES) | 1997-02-20 | — | — | WO | claimed |
| WO-1996040150-A1 | TREATMENT AND PREVENTION OF PROSTATIC DISEASE | MERCK & CO., INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0748220-A1 | METHODS AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R-(-)-CASODEX | SEPRACOR, INC. (US) | 1996-12-18 | — | — | EP | claimed |
| EP-0724592-A1 | 16-SUBSTITUTED-4-AZA-ANDROSTANE 5-ALPHA-REDUCTASE ISOZYME 1 INHIBITORS | MERCK & CO. INC. (US) | 1996-08-07 | — | — | EP | claimed |
| WO-1996003875-A1 | COMPOSITIONS FOR TARGETING MATERIALS TO CELLS CONTAINING ANDROGEN RECEPTORS | EMORY UNIVERSITY (US) | 1996-02-15 | — | — | WO | claimed |
| WO-1995019770-A1 | METHODS AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R-(-)-CASODEX | SEPRACOR, INC. (US) | 1995-07-27 | — | — | WO | claimed |
| WO-1995013077-A1 | 7β-SUBSTITUTED-4-AZA-5α-CHOLESTAN-3-ONES AS SELECTIVE 5α-REDUCTASE 1 INHIBITORS | MERCK & CO., INC. (US) | 1995-05-18 | — | — | WO | claimed |
| WO-1995011254-A1 | 16-SUBSTITUTED-4-AZA-ANDROSTANE 5-ALPHA-REDUCTASE ISOZYME 1 INHIBITORS | MERCK & CO., INC. (US) | 1995-04-27 | — | — | WO | claimed |
| EP-0595796-A1 | METHOD OF TREATMENT OF ANDROGEN-RELATED DISEASES | ENDORECHERCHE INC. (CA) | 1994-05-11 | — | — | EP | claimed |
| WO-1991000733-A1 | METHOD OF TREATMENT OF ANDROGEN-RELATED DISEASES | ENDORECHERCHE INC. (CA) | 1991-01-24 | — | — | WO | claimed |